Cardiovascular Systems Inc. received the CE Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360º is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD).

Future prevention and treatment strategies for vascular diseases may lie in the evaluation of early brain imaging tests long before heart attacks or strokes occur, according to a systematic review conducted by a team of cardiologists, neuroscientists, and psychiatrists from Icahn School of Medicine at Mount Sinai and published in the October issue of JACC Cardiovascular Imaging.

Enrollment is open for the Dual Epicardial and Endocardial Procedure (DEEP) clinical trial following U.S Food and Drug Administration Approval (FDA).

Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of peripheral artery disease (PAD), at the Vascular Interventional Advances (VIVA) Annual Conference taking place Nov. 4-7 in Las Vegas.

A diverse group of uncommon congenital heart defects and genetic conditions may put a child in danger of sudden cardiac arrest (SCA), and at least two-thirds of these defects and conditions can be identified by an electrocardiogram (ECG), the test that analyzes the heart's electrical function. Much of the current debate centers on the practicalities and cost of universal ECG screening. Two clinicians offer opposing commentaries on the controversy in the August 19 issue of Circulation, the journal of the American Heart Association.